{
    "name": "hepatitis B immune globulin (HBIG)",
    "comment": "Rx",
    "other_names": [
        "h big",
        "Hep B Gammagee",
        "HepaGam B",
        "HyperHep",
        "HyperHEP B S/D"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/nabi-h-b-hepagam-b-hepatitis-b-immune-globulin-343136",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Not known if excreted in breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not known if excreted in breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to human globulin",
                "Severe thrombocytopenia or coagulation disorders"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "IgA deficiency, thrombocytopenia, coagulopathies",
                "May elevate alkaline phosphatase, AST, creatinine",
                "May decrease WBC",
                "Use caution in patients with bleeding disorders",
                "Thrombotic events reported",
                "Do NOT give IV",
                "Separate live vaccines by 3 months"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "hepatitis B immune globulin (HBIG), tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of BCG vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of hepatitis B immune globulin (HBIG) by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "hepatitis B immune globulin (HBIG) decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of hepatitis B immune globulin (HBIG) by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "14"
        },
        {
            "name": "Erythema",
            "percent": "12"
        },
        {
            "name": "Myalgia",
            "percent": "10"
        },
        {
            "name": "Malaise",
            "percent": "6"
        },
        {
            "name": "Nausea",
            "percent": "4"
        },
        {
            "name": "Generalized pain",
            "percent": "4"
        },
        {
            "name": "injection site pain",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Ecchymosis",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Chest tightness",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "Angioneurotic edema",
            "percent": null
        },
        {
            "name": "Nephrotic syndrome",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        }
    ]
}